<DOC>
	<DOC>NCT00859027</DOC>
	<brief_summary>Men treated with neoadjuvant luteinizing hormone-releasing hormone (LHRH)-agonists such as leuprolide and goserelin for prostate cancer will become hypogonadal due to hormonal suppression and demonstrate increased bone turnover and consequent bone loss at the hip and spine. This bone loss can be prevented by treatment with 35 mg/week of risedronate.</brief_summary>
	<brief_title>Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<criteria>Nonmetastatic prostate cancer Men to receive Gonadotropinreleasing Hormoneagonist therapy Other cancers except skin cancer Evidence of metabolic bone disease Prior use of bisphosphonates</criteria>
	<gender>Male</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Non-metastatic</keyword>
</DOC>